BCWorld Healthcare and ReGelTec have entered into an exclusive distribution agreement for HYDRAFIL™ in the South Korean market
BCWorld Healthcare also made an investment in ReGelTec and the companies are working together to secure regulatory approval in South Korea
ReGelTec’s HYDRAFIL Technology Selected as Best Abstract Presentation
Clinical studies show chronic low back pain decreased by more than 80% in 60 patients at three months.
Injected ‘Hydrogel’ May Be New Option Against Back Pain
Like fixing a flat on the roadside, a new injectable hydrogel is showing promise as a remedy for worn-down spinal discs -- pumping them back up and relieving chronic back pain.
Early study suggests a new, injectable gel may greatly reduce chronic low back pain
An experimental formulation of a hydrogel, injected into spinal discs, proved safe and effective in substantially relieving chronic low back pain caused by degenerative disc disease (DDD), according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting, in Boston.
5 Questions with Bill Niland, CEO, ReGelTec, Inc.
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated.
ReGelTec Presents Early Feasibility Study at ASSR Annual Meeting
ReGelTec, Inc., a clinical stage medical device company developing HYDRAFIL™, a percutaneous treatment for chronic low back pain, announced the presentation of Early Feasibility Study (EFS) results by Dr Alfonso Spath at the American Society of Spine Radiology annual meeting that took place February 19-21, 2021.